CAR-T cell therapy in Multiple Myeloma: current status and future challenges
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
CAR-T cell therapy in Multiple Myeloma: current status and future challenges ; volume:14 ; number:1 ; day:26 ; month:11 ; year:2024 ; pages:1-16 ; date:12.2024
Blood cancer journal ; 14, Heft 1 (26.11.2024), 1-16, 12.2024
- Urheber
-
Swan, Dawn
Madduri, Deepu
Hocking, Jay
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41408-024-01191-8
- URN
-
urn:nbn:de:101:1-2502112119041.038768777215
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:34 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Swan, Dawn
- Madduri, Deepu
- Hocking, Jay
- SpringerLink (Online service)
Ähnliche Objekte (12)
CAR-T cells in multiple myeloma: current status
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
Non‐BCMA targeted CAR‐T cell therapies for multiple myeloma
Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors
Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies
Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
Establishing guidelines for CAR-T cells: challenges and considerations
CAR-T Therapies in Solid Tumors: Opportunities and Challenges
Engineering CAR-T cells
Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma
CAR-T therapy alters synthesis of platelet-activating factor in multiple myeloma patients
An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously
CAR-T cells in multiple myeloma: current status
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
Non‐BCMA targeted CAR‐T cell therapies for multiple myeloma
Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors
Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies
Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
Establishing guidelines for CAR-T cells: challenges and considerations
CAR-T Therapies in Solid Tumors: Opportunities and Challenges
Engineering CAR-T cells
Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma
CAR-T therapy alters synthesis of platelet-activating factor in multiple myeloma patients
An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously
CAR-T cells in multiple myeloma: current status
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
Non‐BCMA targeted CAR‐T cell therapies for multiple myeloma
Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors
Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies
Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
Establishing guidelines for CAR-T cells: challenges and considerations
CAR-T Therapies in Solid Tumors: Opportunities and Challenges
Engineering CAR-T cells
Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma
CAR-T therapy alters synthesis of platelet-activating factor in multiple myeloma patients